Illumina completed the deal last year, even as regulators in the United States and Europe raised concerns that an Illumina-owned Grail could stifle innovation of competing early cancer detection tests.
Illumina completed the deal last year, even as regulators in the United States and Europe raised concerns that an Illumina-owned Grail could stifle innovation of competing early cancer detection tests.
